Article
Medicine, General & Internal
Sarang Hong, Dae Wook Hwang, Jae Hoon Lee, Ki Byung Song, Woohyung Lee, Bong Jun Kwak, Yejong Park, Song-Cheol Kim
Summary: The high modified Glasgow Prognostic Score (mGPS) is independently associated with poor overall survival and disease-free survival in patients undergoing curative surgery for pancreatic ductal adenocarcinoma (PDAC), especially for those with TNM stage I PDAC and tumors located at the pancreatic head or uncinate process. Preoperative mGPS is a significant prognostic factor for PDAC after curative resection.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Robyn D. Gartrell, Thomas Enzler, Pan S. Kim, Benjamin T. Fullerton, Ladan Fazlollahi, Andrew X. Chen, Hanna E. Minns, Subha Perni, Stuart P. Weisberg, Emanuelle M. Rizk, Samuel Wang, Eun Jeong Oh, Xinzheng Guo, Codruta Chiuzan, Gulam A. Manji, Susan E. Bates, John Chabot, Beth Schrope, Michael Kluger, Jean Emond, Raul Rabadan, Donna Farber, Helen E. Remotti, David P. Horowitz, Yvonne M. Saenger
Summary: Despite complete surgical resection and intense systemic therapies, patients with pancreatic ductal adenocarcinoma (PDAC) have a poor prognosis. Immunotherapies have almost uniformly failed in the treatment of PDAC. This study found that while chemoradiation therapy (CRT) can achieve high T cell densities in PDAC compared to melanoma, the phenotype and spatial organization of T cells may limit the benefit of T cell infiltration in this immunotherapy-resistant tumor.
Review
Biochemistry & Molecular Biology
Nausika Betriu, Juan Bertran-Mas, Anna Andreeva, Carlos E. Semino
Summary: Syndecans, a subfamily of proteoglycans, play critical roles in various physiological processes and have implications in disease progression. Their interactions with other macromolecules contribute to normal cellular functions and disease pathogenesis.
Article
Oncology
Lingyu Zhu, Shuo Shen, Huan Wang, Guoxiao Zhang, Xiaoyi Yin, Xiaohan Shi, Suizhi Gao, Jiawei Han, Yiwei Ren, Jian Wang, Hui Jiang, Shiwei Guo, Gang Jin
Summary: The AJCC staging system was revised to be consistent with upfront surgery and neoadjuvant therapy for pancreatic ductal adenocarcinoma (PDAC) to improve prediction. The NATCP staging system demonstrated greater predictive abilities than the existing AJCC staging approach for resected PDAC patients.
Article
Oncology
Yi Tat Tong, Zongshan Lai, Matthew H. G. Katz, Laura R. Prakash, Hua Wang, Deyali Chatterjee, Michael Kim, Ching-Wei D. Tzeng, Jeffrey E. E. Lee, Naruhiko Ikoma, Asif Rashid, Robert A. Wolff, Dan Zhao, Eugene J. Koay, Anirban Maitra, Huamin Wang
Summary: Our study examined the clinicopathologic factors and survival of 213 pancreatic ductal adenocarcinoma patients treated with FOLFIRINOX and gemcitabine/nab-paclitaxel therapies. We found that FOLFIRINOX group had a better pathologic response and identified the tumor response group, ypN, ypT, LVI, and PNI as significant prognostic factors for survival.
Review
Radiology, Nuclear Medicine & Medical Imaging
Chao Qu, Piao-e Zeng, Hang-yan Wang, Chun-hui Yuan, Hui-shu Yuan, Dian-rong Xiu
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a deadly tumor of the digestive system. Neoadjuvant treatment has been recommended to increase surgical resection rate and improve survival. However, current evaluation systems are not accurate enough, and magnetic resonance imaging (MRI) shows potential in assessing PDAC neoadjuvant treatment. Further development is needed for better assessment.
JOURNAL OF MAGNETIC RESONANCE IMAGING
(2022)
Article
Pathology
Aaron J. Sohn, Mehran Taherian, Matthew H. G. Katz, Laura R. Prakash, Deyali Chatterjee, Hua Wang, Michael Kim, Ching-Wei D. Tzeng, Jeffrey E. Lee, Naruhiko Ikoma, Asif Rashid, Robert A. Wolff, Dan Zhao, Eugene J. Koay, Ryan Sun, Anirban Maitra, Huamin Wang
Summary: A multifactorial prognostic score, the integrated pathologic score (IPS), combining pathologic features including ypT, ypN, and TRG, can provide improved prognostic information for patients with preoperatively treated PDAC compared with AJCC staging. Higher IPS is associated with shorter DFS and OS.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
(2023)
Article
Surgery
Sami Shoucair, Jianan Chen, James R. Martinson, Joseph R. Habib, Benedict Kinny-Koster, Ning Pu, A. Floortje van Oosten, Ammar A. Javed, Ji Shin, Syed Z. Ali, Kelly J. Lafaro, Christopher L. Wolfgang, Jin He, Jun Yu
Summary: Assessment of protein expression on fine-needle aspiration biopsy specimens can predict the pathologic response to neoadjuvant therapy in treatment-naive patients with pancreatic ductal adenocarcinoma.
Article
Gastroenterology & Hepatology
Takeshi Tanaka, Atsuhiro Masuda, Jun Inoue, Tsuyoshi Hamada, Takuya Ikegawa, Hirochika Toyama, Keitaro Sofue, Hideyuki Shiomi, Arata Sakai, Takashi Kobayashi, Shunta Tanaka, Ryota Nakano, Yasutaka Yamada, Shigeto Ashina, Masahiro Tsujimae, Kohei Yamakawa, Shohei Abe, Masanori Gonda, Shigeto Masuda, Noriko Inomata, Hisahiro Uemura, Shinya Kohashi, Kae Nagao, Maki Kanzawa, Tomoo Itoh, Yoshihide Ueda, Takumi Fukumoto, Yuzo Kodama
Summary: Background: Tertiary lymphoid structure (TLS) reflects intense immune response against cancer and is associated with favorable patient survival. However, its association with tumor-infiltrating lymphocytes (TILs) and clinical outcomes in pancreatic ductal adenocarcinoma (PDAC) has not been thoroughly investigated. Methods: An integrative molecular pathological epidemiology database was used to examine TLS in relation to TIL levels, patient survival, and treatment response in 162 cases of resected PDAC. Conclusions: Our comprehensive data supports the surrogacy of TLS for vigorous anti-tumor immune response characterized by high levels of helper and cytotoxic T cells and their prognostic role.
JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Oncology
Yen-Yang Chen, Shun-Wen Hsueh, Shih-Hung Yang, Sz-Chi Chiu, Nai-Jung Chiang, Tai-Jan Chiu, Chung-Pin Li, Li-Yuan Bai, Chang-Fang Chiu, Shih-Chang Chuang, Yan-Shen Shan, De-Chuan Chan, Li-Tzong Chen, Chia-Jui Yen, Cheng-Ming Peng, Jen-Shi Chen, Wen-Chi Chou
Summary: Combining albumin with the neutrophil-to-lymphocyte ratio (NLR) as the albumin and neutrophil-to-lymphocyte ratio score (ANS) can serve as a simple tool to predict survival and safety profiles in PDAC patients refractory to gemcitabine-based therapy. Higher ANS scores are associated with shorter overall survival and higher incidence of treatment-related adverse events.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Article
Oncology
Siming Gao, Wenjie Tang, Bingli Zuo, Lianne Mulvihill, Jinming Yu, Yishan Yu
Summary: This study investigates the predictive role of neutrophil-to-lymphocyte ratio (NLR) in overall survival (OS) and pathologic complete response (pCR) in breast cancer patients undergoing neoadjuvant chemotherapy (NAC). A total of 501 patients were included in the retrospective analysis, and it was found that NLR was correlated with OS and pCR. A novel model for predicting OS was established, and it was also observed that non-pCR patients experienced an increase in NLR during NAC.
FRONTIERS IN ONCOLOGY
(2023)
Article
Gastroenterology & Hepatology
Olivier Caliez, Daniel Pietrasz, Feryel Ksontini, Solene Doat, Jean-Marc Simon, Jean-Christophe Vaillant, Valerie Taly, Pierre Laurent-Puig, Jean-Baptiste Bachet
Summary: This study aimed to investigate the impact of baseline circulating tumor DNA status on treatment and prognosis of patients with borderline resectable or locally advanced pancreatic adenocarcinoma. The results showed that positive baseline ctDNA was associated with shorter progression-free survival and shorter relapse-free survival after secondary resection.
DIGESTIVE AND LIVER DISEASE
(2022)
Article
Oncology
Esmeralda Garcia-Torralba, Esther Navarro Manzano, Gines Luengo-Gil, Pilar De la Morena Barrio, Asuncion Chaves Benito, Miguel Perez-Ramos, Beatriz Alvarez-Abril, Alejandra Ivars Rubio, Elisa Garcia-Garre, Francisco Ayala de la Pena, Elena Garcia-Martinez
Summary: This study aimed to analyze the predictive capacity of several markers associated with immune response and cell proliferation combined with clinical parameters in breast cancer patients treated with neoadjuvant chemotherapy. The results showed that neutrophil-to-lymphocyte ratio (NLR), tumor-infiltrating lymphocytes (TILs), AURKA, and MYBL2 have prognostic value for overall survival. These biomarkers may provide valuable information for the management of early breast cancer patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Rong Liu, Ya-Zhou Liao, Wei Zhang, Hong-Hao Zhou
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with high heterogeneity and poor survival rates. The study identified specific immune cell types closely associated with the survival rate and chemotherapy sensitivity of PDAC patients, and different immune cell subgroups have different effects on the survival pattern and chemotherapy response of PDAC patients. High expression of PD1 is associated with better overall survival. The study suggests that exploring the immune cellular composition infiltrate in PDAC may help identify candidates for immunotherapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Youzhao Ma, Jingyang Zhang, Xiuchun Chen
Summary: This study demonstrated that LMR can serve as a potential marker for predicting the efficacy and prognosis of patients with breast cancer. Patients with low LMR, HER-2 positive, and lymph node status (N2-3) showed poor disease-free survival outcomes.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Oncology
Anna M. Varghese, Isha Singh, Rituraj Singh, Siddharth Kunte, Joanne F. Chou, Marinela Capanu, Winston Wong, Maeve A. Lowery, Zsofia K. Stadler, Erin Salo-Mullen, Lily Saadat, Alice C. Wei, Marsha Reyngold, Olca Basturk, Ryma Benayed, Diana Mandelker, Christine A. Iacobuzio-Donahue, David P. Kelsen, Wungki Park, Kenneth H. Yu, Eileen M. O'Reilly
Summary: The study reported the epidemiologic, pathologic, and molecular characteristics of a patient cohort with early-onset pancreas cancer, finding that pathogenic germline variants (PGVs) are present in a substantial minority of patients and actionable somatic alterations are enriched in the RAS wild-type subgroup.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2021)
Article
Surgery
Joshua S. Jolissaint, Marsha Reyngold, Jared Bassmann, Kenneth P. Seier, Mithat Gonen, Anna M. Varghese, Kenneth H. Yu, Wungki Park, Eileen M. O'Reilly, Vinod P. Balachandran, Michael I. D'Angelica, Jeffrey A. Drebin, T. Peter Kingham, Kevin C. Soares, William R. Jarnagin, Christopher H. Crane, Alice C. Wei
Summary: Ablative dose radiotherapy shows promising effects in localized pancreatic ductal adenocarcinoma (PDAC) treatment, offering similar locoregional disease control as resection but weaker results in distant recurrence/progression.
Editorial Material
Oncology
Quisette P. Janssen, Jacob L. van Dam, Isabelle G. Kivits, Marc G. Besselink, Casper H. J. van Eijck, Marjolein Y. V. Homs, Joost J. M. E. Nuyttens, Hongchao Qi, Hjalmar J. van Santvoort, Alice C. Wei, Roeland F. de Wilde, Johanna W. Wilmink, Geertjan van Tienhoven, Bas Groot Koerkamp
ANNALS OF SURGICAL ONCOLOGY
(2021)
Review
Oncology
Quisette P. Janssen, Jacob L. van Dam, Isabelle G. Kivits, Marc G. Besselink, Casper H. J. van Eijck, Marjolein Y. V. Homs, Joost J. M. E. Nuyttens, Hongchao Qi, Hjalmar J. van Santvoort, Alice C. Wei, Roeland F. de Wilde, Johanna W. Wilmink, Geertjan van Tienhoven, Bas Groot Koerkamp
Summary: In this meta-analysis, radiotherapy following neoadjuvant FOLFIRINOX was associated with an improved R0 resection rate as compared with neoadjuvant FOLFIRINOX alone, but a difference in survival could not be demonstrated. Randomized trials are needed to determine the added value of radiotherapy following neoadjuvant FOLFIRINOX in patients with (B)PRC.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Lily Saadat, Joanne F. Chou, Mithat Gonen, Kevin C. Soares, T. Peter Kingham, Anna M. Varghese, William R. Jarnagin, Michael D'Angelica, Jeffrey A. Drebin, Eileen M. O'Reilly, Alice C. Wei
Summary: This study compared treatment utilization for early-onset pancreatic cancer (EOPC) versus average-age-onset pancreatic cancer (AOPC) and found that EOPC patients receive more oncologic therapy, but still 19% of patients do not receive any treatment. Patients with AOPC more frequently decline chemotherapy, and one-year survival rate of EOPC patients is significantly higher than that of AOPC patients.
Article
Oncology
Saptarshi Chakraborty, Brett L. Ecker, Ken Seier, Victoria G. Aveson, Vinod P. Balachandran, Jeffrey A. Drebin, Michael I. D'Angelica, T. Peter Kingham, Carlie S. Sigel, Kevin C. Soares, Efsevia Vakiani, Alice C. Wei, Rohit Chandwani, Mithat Gonen, Ronglai Shen, William R. Jarnagin
Summary: The study investigates the clinical behavior of ampullary adenocarcinoma and the impact of targeted tumor sequencing on defining biologically distinct subtypes. Results show that genomic classification is influenced by specific gene mutations, tumor mutational burden, and DNA mismatch repair deficiency. The study highlights the importance of genomic stratification in improving diagnosis and management of ampullary adenocarcinoma.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Pablo E. Serrano, Sameer Parpia, Paul Karanicolas, Steven Gallinger, Alice C. Wei, Marko Simunovic, Mohit Bhandari, Mark Levine
Summary: The study tested the feasibility of a simultaneous resection clinical trial in patients with synchronous colorectal cancer liver metastases, showing a high feasibility but higher than anticipated postoperative complication rate.
JOURNAL OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Caitlin A. McIntyre, Noah A. Cohen, Debra A. Goldman, Mithat Gonen, Eran Sadot, Eileen M. O'Reilly, Anna M. Varghese, Kenneth H. Yu, Vinod P. Balachandran, Kevin C. Soares, Michael D'Angelica, Jeffrey A. Drebin, T. P. Kingham, Peter J. Allen, Alice C. Wei, William R. Jarnagin
Summary: The study evaluated the outcomes of patients with locally advanced pancreatic adenocarcinoma who received induction FOLFIRINOX treatment, finding that nearly 20% of patients responded sufficiently to be eligible for surgery and had improved survival compared to those who did not undergo surgery. Furthermore, patients with stable disease who remained unresectable may benefit from optimization of nonoperative treatments.
JOURNAL OF SURGICAL ONCOLOGY
(2022)
Article
Gastroenterology & Hepatology
Victoria G. Aveson, Crisanta H. Ilagan, Joanne F. Chou, Mithat Gonen, Vinod P. Balachandran, Jeffrey A. Drebin, William R. Jarnagin, Alice C. Wei, T. Peter Kingham, Michael D'Angelica
Summary: A retrospective study on patients with perihilar cholangiocarcinoma (PHC) showed that transperitoneal biopsy is not associated with an increased risk of peritoneal metastases (PM).
Article
Oncology
Alice C. C. Wei
Summary: Important new studies have revealed new treatment options for patients with liver and biliary malignancies, including immune checkpoint inhibition and precision oncology approaches. These findings have significant implications for improving patient outcomes.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Mengyuan Liu, Alice C. Wei
ANNALS OF SURGICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Lily V. Saadat, Alice C. Wei
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Surgery
Misha T. Armstrong, Max Murray-Ramcharan, James H. Flory, William R. Jarnagin, Alice C. Wei
BRITISH JOURNAL OF SURGERY
(2023)
Review
Surgery
Travis L. Williams, Lily V. Saadat, Mithat Gonen, Alice Wei, Richard K. G. Do, Amber L. Simpson
Summary: Surgery combined with chemotherapy has shown promising results in certain cancer types, but there is still controversy over the optimal timing and patient selection for neoadjuvant or adjuvant strategies. Radiomics combined with machine learning has the potential to predict tumor behavior and response to therapy, but faces challenges such as lack of standardization in practices and limited data sharing that hinder its widespread adoption.
COMPUTER ASSISTED SURGERY
(2021)